Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1/2 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Other hematologic neoplasm 1

Conditions

Carcinoma, Renal Cell 2Renal Insufficiency 1Kidney Failure, Chronic 1

Interventions

pembrolizumab 182Magnetic Resonance Spectroscopy 163Specimen Handling 135enzalutamide 126Nivolumab 124Gemcitabine 99Docetaxel 96Radiosurgery 92Prednisone 85Androgen Antagonists 82Abiraterone Acetate 81Radiotherapy 75apalutamide 68Cisplatin 65darolutamide 63Ipilimumab 63Biopsy 60abiraterone 58Carboplatin 56cabozantinib 55Leuprolide 53enfortumab vedotin 49Radiation 48Pluvicto 45Standard of Care 44atezolizumab 40Surveys and Questionnaires 39acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 37X-Rays 37avelumab 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Kidney Transplantation × Genitourinary × 1 year × Clear all
NCT05725421 2026-05-28

Transplantation of Reconstructed Renal Allografts Following Ex-Vivo Partial Nephrectomy

Case Comprehensive Cancer Center

Phase NA Withdrawn
Genitourinary

Carcinoma, Renal Cell

NCT07053462 2025-07-08

CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk

AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC

Phase 1/2 Recruiting
90 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Failure, Chronic, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡